NVO•benzinga•
Novo Nordisk Says CagriSema Demonstrates Weight Loss In Adults With Obesity Or Overweight In The REDEFINE 1 Trial; Company Says Trial Achieved Its Primary Endpoint By Demonstrating Weight Loss At Week 68 With CagriSema Versus Placebo
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 20, 2024 by benzinga